Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid?

Sahoo, Sushree Monika; Mahapatra, Soumya Jagannath

doi:10.1016/s2468-1253(21)00306-x

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the treatment, patients in both groups had significantly lower pruritus scores, bile acid levels, and the levels of ALT, AST, TB, and CG, which were lower in the patients of the combined group than those of the control group ( P < 0.05), indicating that polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine 1,4-butanedisulfonate mitigated the pruritus, reduced bile acid levels, lowered the liver enzyme indices, and facilitated the recovery of liver function, with better compared to ursodeoxycholic acid/ademetionine 1,4-butanedisulfonate. The efficacy of ursodeoxycholic acid has been recognized in the existing clinical treatment of gallstone disease and cholestatic disorders[ 14 ]. Cholestatic liver disease is associated with the accumulation of goose deoxycholic acid, deoxycholic acid, and stone bile acids.…”

Section: Discussionmentioning

confidence: 99%

Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis

Dong,

Chen,

Xue

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

In recent years, metabolomics research has become a hot spot in the screening and treatment of cancer. It is a popular technique for the quantitative characterization of small molecular compounds in biological cells, tissues, organs or organisms. Further study of the tumor revealed that amino acid changes may occur early in the tumor. The rapid growth and metabolism required for survival result in tumors exhibiting an increased demand for amino acids. An abundant supply of amino acids is important for cancer to maintain its proliferative driving force. Changes in amino acid metabolism can be used to screen malignant tumors and improve therapeutic outcomes. Therefore, it is particularly important to study the characteristics of amino acid metabolism in colorectal cancer. This article reviews several specific amino acid metabolism characteristics in colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis

Dong,

Chen,

Xue

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…Intrahepatic cholestasis of pregnancy (ICP) is one of the most common liver disorders during pregnancy, with a reported incidence rate ranging from 0.2 to 2% [ 1 ]. ICP typically occurs in the middle or late stages and rarely at the early stages of pregnancy [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Proteomic Biomarkers of Intrahepatic Cholestasis of Pregnancy

Zeng,

Hou,

et al. 2024

Reprod. Sci.

View full text Add to dashboard Cite

Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disease, which can lead to adverse fetal outcomes, including preterm labor and intrauterine death. The pathogenesis of ICP is still unclear. We hypothesized that pathological index leads to abnormal placenta changes in ICP. Investigation of these differences in protein expression in parallel profiling is essential to understand the comprehensive pathophysiological mechanism underlying ICP. The present study screened differentially expressed proteins (DEPs) as novel diagnostic markers for ICP. Proteomic profiles of placental tissues from 32 ICP patients and 24 healthy volunteers (controls) were analyzed. Our founding was valid by following western blotting and immunohistochemistry staining, respectively. The association of the key protein expression with clinicopathological features of ICP was further analyzed. A total of 178 DEPs were identified between the ICP and control groups. Functional enrichment analysis showed these proteins were significantly enriched in the PPAR singling pathway by KEGG and PPARα/RXRα activation by IPA. Apolipoprotein A2 (APOA2) was the only upregulated protein, which uniquely identified in ICP groups and related to both pathways. Validation of western blotting and immunohistochemical staining analysis showed significantly higher APOA2 expression in the ICP group than in the control group. Furthermore, the expression of APOA2 is associated with clinicopathological features in ICP groups. Receiver operating characteristic (ROC) curve analyses showed that the AUC of APOA2 was 0.8984 (95% confidence interval (CI): 0.772–1.000). This study has identified up-regulated APOA2 associated with PPAR singling pathway and PPARα/RXRα activation in ICP. Thus, APOA2 may be involved in ICP pathogenesis, serving as a novel biomarker for its diagnosis.

show abstract

Comprehensive analysis of placental gene-expression profiles and identification of EGFR-mediated autophagy and ferroptosis suppression in intrahepatic cholestasis of pregnancy

Fang¹,

Fang²

2022

Gene

View full text Add to dashboard Cite

Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid?

Cited by 3 publications

References 4 publications

Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis

Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis

Proteomic Biomarkers of Intrahepatic Cholestasis of Pregnancy

Comprehensive analysis of placental gene-expression profiles and identification of EGFR-mediated autophagy and ferroptosis suppression in intrahepatic cholestasis of pregnancy

Contact Info

Product

Resources

About